| Cat.No. | Name | Information |
|---|---|---|
| M40804 | Rimegepant Sulfate | Rimegepant Sulfate is a potent, selective, competitive, orally active calcitonin gene-related peptide (CGRP) antagonist with a Ki of 0.027 nM.May be used in migraine-related studies. |
| M40614 | Calcitonin (human) | Calcitonin (human) is a calcitonin that lowers blood calcium levels and inhibits bone resorption and may be used in studies related to hypercalcemia or osteoporosis. |
| M28370 | Cagrilintide acetate | Cagrilintide acetate is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity. |
| M28198 | Vazegepant | Vazegepant is the first intranasal CGRP receptor antagonist for the study the acute research of migraine. |
| M25531 | α-CGRP, human TFA | α-CGRP, human TFA is a regulatory neuropeptide of 37 amino acids. α-CGRP, human TFA can be used as a potent vasodilator. |
| M13935 | Rat CGRP-(8-37) | Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist. |
| M13933 | MK-3207 | MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3. |
| M13932 | HCGRP-(8-37) | HCGRP-(8-37) is a human calcitonin gene-related peptide (hCGRP) fragment and also an antagonist of CGRP receptor. |
| M10894 | Ubrogepant | Ubrogepant (MK-1602) is a novel oral calcitonin gene-associated peptide receptor (CGRP) antagonist with the potential to be used in acute migraine studies. |
| M10801 | Calcitonin (salmon) | Calcitonin salmon is a calcium-regulating hormone that is a dual agonist of amylin and calcitonin receptors that stimulate bone production and inhibit bone resorption. |
| M10372 | Vazegepant hydrochloride | Vazegepant (BHV-3500) hydrochloride is a highly affinity CGRP receptor antagonist (hCGRP Ki= 0.023 nM). |
| M9165 | Rimegepant | Rimegepant, also known as BMS-927711, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist with a Ki value of 0.027 nM. |
| M6504 | Olcegepant (BIBN-4096) | Olcegepant (BIBN-4096) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide (CGRP) receptor with IC50 of 0.03 nM and Ki of 14.4 pM for human CGRP. |
| M5240 | BAR 501 impurity | |
| M5223 | BAR501 | BAR501 is a potent and selective agonist of GPBAR1 with an EC50 of 1 μM. |
| M3618 | MK-0974 | MK-0974 (Telcagepant) is a highly potent, selective and orally bioavailable CGRP receptor antagonist with Ki values of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors respectively. |
| M2133 | MK-3207 hydrochloride | MK-3207 hydrochloride is a potent CGRP receptor antagonist with IC50 of 0.12 nM. |
| M24777 | Fremanezumab | Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research. |
| M24771 | Eptinezumab | Eptinezumab is a human monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Eptinezumab can be used for the prevention of migraine in adults. |
| M24721 | Erenumab | Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
